Destiny Pharma PLC (AIM:DEST) presenting at the Proactive One2One Virtual Forum

Destiny Pharma PLC (AIM:DEST) (Destiny Pharma PLC (AIM:DEST)) presenting at the Proactive One2One Virtual Forum – 17th March 2022

Destiny Pharma PLC (Destiny Pharma PLC (AIM:DEST)) is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. The company’s pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infections in the US. Destiny’s pipeline also includes XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. The company is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.